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Abstract
We identify three properties of the standard oncology phase I trial design or 3 + 3 design.
We show that the standard design implicitly uses isotonic regression to estimate a maximum
tolerated dose. We next illustrate the relationship between the standard design and a Bayesian
design proposed by Ji et al. (2007). A slight modification to this Bayesian design, under a
particular model specification, would assign treatments in a manner identical to the standard
design. We finally present calculations revealing the behavior of the standard design in a worst
case scenario and compare its behavior with other 3 + 3-like designs.
1 Introduction
The main goal of an oncology phase Ia clinical trial is to assess the safety of a drug which has
not yet been tested in humans (Arbuck, 1996). A well designed oncology phase I trial should
yield enough information to determine a safe dose, or range of safe doses, to use in further trials,
while maintaining a reasonably low level of risk to the patients in the study. The dose or doses
to be used for further study should be low enough to be safe for most patients, but high enough
to be efficacious, since higher doses are often more effective. While the ‘more is better’ paradigm
is well accepted in the case of chemotherapeutic agents, it is not clear that this paradigm should
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hold for newer, targeted, non-chemotherapeutic cancer agents. That is not to say that many or
most of the newer molecularly targeted agents are not more efficacious in higher doses, but that
it is not a given that the ‘more is better’ paradigm always holds.
The primary scientific question in an oncology phase Ia study dictates to some extent the
type of patient who would enroll in such a study. Patients who have standard of care treatment
available to them are less likely to participate in a phase I oncology study, and as a result,
the patient population is often a heterogeneous group of patients with different types of late
stage cancer. Different types of cancer often suggest different risk-benefit tolerances by both
the patient and the treating clinician. This may result in a difficulty in selecting a trial design
due to the existence and validity of multiple risk-benefit ratios. For example, a patient with
metastatic pancreatic cancer may be willing to risk more toxicity than a patient with newly
diagnosed late stage prostate cancer. This may result in the uncomfortable situation where the
same adverse reaction has different implications for future development depending on the type
of disease the patients has. In general, Phase I protocols report so called, dose-limiting toxicities
(DLTs), irrespective of the type of disease the patient has. Additionally, the developers of a
new oncology therapy may not know, before the first human data is generated in phase Ia, all
the types of cancer to target in future phase II and III studies. This may be due to unexpected,
dramatic results in phase Ia and/or changes in the financial resources of the entity developing
the therapy. Another complicating reality is that assigning attribution of patient outcomes to
the therapy under investigation, a patient’s cancer, or a patient’s concomitant medication is not
an exact science. This is especially true when therapeutic agents are being tested for the first
time in humans. Early on in testing, it is not uncommon for a patient’s outcome to be deemed
a DLT only after a number of other patients have experienced the same outcome and/or degree
of severity. An outcome determined to be a DLT after patients have started treatment in higher
dose levels may result in a protocol specified action which is different than the action already
taken had the DLT been identifier earlier. These realities are rarely discussed in the literature
for consideration of a phase I design, which further complicates the mission of designing the
‘best’ phase Ia trial.
Unlike the phase II or III paradigm, where the objective is to assess efficacy while obtain-
ing valuable safety information, phase I studies often necessitate the administration of unsafe
amounts of drug to some patients in order to determine a maximum tolerable dose, or range of
safe doses. And as in all clinical studies, the trial should not involve too many patients or take
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too long to complete. One can find many methods for dose finding in the literature, the “stan-
dard design” (Storer, 1989) being the oldest of the commonly employed phase I designs. Other
designs contained in the literature include continual reassessment (O’Quigley et al., 1990), ran-
dom walk (Durham and Flournoy, 1994), escalation with overdose control (Babb et al., 1998),
and cumulative cohort designs (Ivanova et al., 2007). For a more extensive review of various
oncology phase I trial designs, the reader is referred to Rosenberger and Haines (2002), Potter
(2006), and Koyfman et al. (2007). It should be noted that the standard design remains by far
the most commonly used in the phase Ia oncology setting. This is likely due to the ease with
which clinical centers are able to carry out the design, its simplicity, historical performance, and
freedom from model assumptions.
We have observed in the literature that comparisons made with newer competing designs,
almost always using simulations, are usually performed with assumptions that do not reflect
some common uses of the 3 + 3 design. One of these assumptions has to do with dose levels
being fixed a priori at the beginning of the study. For phase Ia studies especially, clinical
investigators are usually not comfortable setting dose escalations before any human data are
available. They prefer to fix the first dose level only and to have future dose escalations be
determined by the accruing toxicity observed in the phase Ia. This is rightly due to the fact that
pre-clinical toxicity information can perform poorly at predicting human toxicities, especially
for newer targeted small molecule therapeutics. This enhancement to the 3 + 3 was introduced
by Simon at al. (1997) as accelerated titration, however its original incarnation referred to
intrapatient escalations. The authors’ motivation for mentioning this fact is due to the belief
that the 3 + 3, while possessing properties which would cause a formally trained statistician
some discomfort (lack of an estimand to name one), it has served drug development relatively
well. We make this comment in the context of new drugs that have yet to be tested in man, the
phase Ia setting. We believe that progress in drug development methods will be surer as the
professed merits and deficiencies of the 3 + 3 are more fairly assessed by accounting for more
current clinical practice.
Recently, Ji et al. (2007) proposed a design similar to the cumulative cohort design, which
uses a Bayesian model to describe the rate of toxicities at each dose. In this design, decisions
about future doses are based on the posterior distributions of toxicity rates at current doses.
These posterior distributions are a function only of the number of patients treated and the
number of patients with toxicities at the current dose. Ji et al. noted that the decision rules
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for their design could be displayed in a monitoring table, where the columns correspond to the
number of patients treated at the current dose level, and the rows correspond to the number of
DLTs at the current dose level. Their work suggested new ways of thinking about phase I trial
designs which inspired our investigation of the relationship between the standard design and
their Bayes design. In the following sections, we will show that the standard design implicitly
uses isotonic regression to estimate a maximum tolerated dose, is related to a special case of
the Ji, Li, Bekele design, and possesses an analytical expression for the upper bound on the
probability of selecting an unsafe final dose.
2 Background
2.1 Terms
In the protocol of an oncology phase Ia study, a DLT will be defined as any of the pre-specified
‘dose limiting’ adverse events that have been determined by the investigator to be related, or
possibly related, to the drug and which occur within a specified temporal window. It should
be noted that regulatory agencies are conservative with respect to assessing the safety of new
therapeutic agents. As a result, any event occurring during the course of the DLT window that
cannot be ruled out as being related to the agent is considered a DLT. These pre-specified ‘dose
limiting’ adverse events are defined as adverse reactions considered to be severe enough to limit
a patient from further exposure to the experimental treatment. These definitions vary from
study to study and are based upon the judgment of the authors of the protocol. A maximum
tolerated dose (MTD) is the highest dose that is considered safe in patients. The standard
design contains a heuristic, and the MTD is defined as the dose that is yielded by applying the
heuristic. While the standard design yields an estimator for the MTD, an explicit estimand is
not defined. Most other designs, including the Ji, Li, Bekele method, do define an estimand as
well as its estimator for the MTD, the estimand being the dose at which a pre-specified fraction
of patients experience a DLT in a well defined patient population. In this article, we use the
term “cohort” to refer to a group of patients treated concurrently and “dose group” to refer to
all the patients who receive a particular dose of drug.
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2.2 The standard design
The standard design, also commonly referred to as the 3+3 design, dictates either fully specified
or partially specified dose level increases. A fully specified escalation scheme sets a starting dose
level and successively increases in future dose levels. For example, dose level increases could
either double the previous level or follow a modified Fibonacci sequence (Omura, 2003). A par-
tially specified escalation scheme also specifies a starting dose level, however, future dose levels
sequentially depend on the number and nature of toxicities experienced and/or pharmacokinetic
or pharmacodynamic measures. In this article, we consider the fully specified escalation scheme
with a pre-specified number of dose levels.
The standard design is defined as having cohort sizes of 3 patients, where no dose level has
more than 2 cohorts. This design begins treating patients at the lowest dose level. If none of
the 3 patients in the first cohort experience a DLT, the next cohort of patients gets treated at
the next higher dose level. If 1 of the 3 patients experiences a 1 DLT, the design assigns another
cohort at the same dose level. If, for some dose level, 2 or more (of 3 or 6) patients experience
DLTs, then that dose level is considered unsafe and is not revisited again during the study, and
the next cohort must be treated at the next lower dose. The trial ends when at most 1 patient
in 6 experiences a DLT, and 2 or more (of 3 or 6) patients experience DLTs at the next highest
dose. The dose group that contains patients treated at the highest dose where at most 1 of 6
patients experience a DLT is determined to be the MTD. There is not a standard approach for
addressing the scenario where the lowest dose level observes a DLT rate of more than 2 out of
6, but two common approaches are to treat the next cohort at some reasonable fraction of the
starting dose or to simply close down the study. Table 1 contains these rules of the standard
design based upon the number of DLTs.
While this design enjoys much popularity among investigators studying new cancer therapies,
it does suffer from the previously mentioned defect that a well defined target, the estimand, is
not known. In general, clinical investigators believe that the standard design determines the dose
which would cause between 17% (1/6) and 33% (2/6) of patients to experience a DLT. This belief
is not completely misguided if one only considers the information contained in patients treated
at the determined MTD to be relevant. However, a more sophisticated view would consider
information contained at all tested dose levels. Under this perspective, the dose level that is
estimated by the design is completely dependent on the true unknown DLT / dose relationship.
For example, the standard design may yield an unbiased estimator of the dose which causes 20%
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of patients to experience a DLT for one DLT / dose relationship versus 30% under a different
DLT / dose relationship. It has been reported in the literature that the standard design had
targeted doses corresponding to a 23% to 28% DLT rate in 22 phase I studies (Smith et al.,
1996). In addition, Lin and Shih (2001) reported that the standard design targeted DLT rates
of 19 to 29% based on 3 distinctly different dose / DLT relationships. Storer (2001) reports
that the standard design is an appropriate design when interest is in identifying a dose which
corresponds to a 20 to 25% DLT rate.
It should be noted that while the standard design requires only 6 patients treated at a
particular dose to determine the MTD, arguably too small a number to gain a reasonable
understanding of an agent’s toxic properties, common practice has become to treat an extra 12
to 18 patients at the MTD in order to gain more experience before designing a phase II clinical
trial. An examination of how this practice affects the properties of this augmented standard
design has not been examined in the literature to the authors’ knowledge, and thus we will not
discuss this case any further for the purposes of this article.
2.3 The Ji, Li, Bekele method
The Ji, Li, Bekele method uses a fully specified dose escalation scheme, and like the standard
design, starts at the lowest dose and escalates dose levels by at most one dose level at a time.
The decision for whether to escalate, stay the same, or de-escalate is based on the number
of patients and the number of DLTs at the current dose. A toxicity exclusion rule prevents
dose escalation if the next higher dose is estimated to be unacceptably toxic based on patient
outcomes at that dose. Cohorts of any size can be specified and the stopping rule is based on a
fixed pre-specified sample size, with the one exception of early stopping when the starting dose
is found unacceptably toxic.
Before we describe the method in detail, we would like to introduce some notation. First, we
will use the integer i to label the dose levels. We define pi to be the true rate of DLTs at dose
level i. We let p denote a vector containing the values pi for all the dose levels. Also, the Ji, Li,
Bekele method requires a user-specified targeted ratio of DLTs which we shall denote by pT .
Using data that becomes available during the course of the study and a Bayesian framework
with an assumed prior on p, Ji, Li, and Bekele propose calculating a probability density for
the probability pi seeing a DLT at the current dose i. The unit interval can be divided into
{(0, pT −K1σi), [pT −K1σi, pT +K2σi], (pT +K2σi, 1)}, where σi is the standard deviation of
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the posterior density of pi, and K1 and K2 are parameters chosen by the researcher. If the
first interval has the most posterior probability mass, then the dose is increased. If the second
interval has the most posterior probability mass, then the dose is kept the same. If the third
interval has the most posterior probability mass, then the dose is de-escalated.
To better control the risk of treating patients at unsafe levels, Ji et al. included a toxicity
exclusion rule, where one computes P (pi > pT ) conditional on the observed data. If this
probability is greater than some user defined quantity ξ, then the dose level i and all higher
doses are considered to be unacceptably toxic and those levels will not be visited again. If the
current dose is one level below an excluded dose, then the action is based on which of the first
two intervals has the most posterior probability mass. The trial ends when the total number
of patients used in the study reaches a pre-specified number or if the starting dose is found
unacceptably toxic.
At the end of the trial, the data and the prior are used to estimate the DLT rate E(pi) = pˆi
at each dose level not ruled out by the toxicity exclusion rule. Next, isotonic regression is
performed on the vector of estimated DLT rates, pˆ. The isotonic regression procedure uses
the weight σ2i at each dose level i and produces a new estimate p
∗ for the DLT rates that is
a monotonically increasing sequence. The estimated MTD is the dose i at which |p∗i − pT | is
minimized. If some doses tie for the smallest difference, and if the mean of p∗i among the ties
is less than pT , then the highest dose among the ties is selected. Otherwise, the lowest dose
among the ties is selected.
3 Isotonic regression and the standard design
The isotonic regression estimator for the MTD has been proposed by Leung and Wang (2001),
Stylianou and Flournoy (2002), Ivanova et al. (2003), and Ji et al. (2007). In simulations
by Ivanova et al., an isotonic regression estimator outperformed both an empirical estimator
and a parametric maximum likelihood estimator for the MTD. We will now show that the
standard design’s method for estimating the MTD is equivalent to an estimator involving isotonic
regression.
In general, isotonic regression is a nonparametric regression technique that yields a fit to a
vector which minimizes the residual sum of squares, subject to the constraint that the fitted
values constitute a monotonically increasing (or decreasing) sequence (Robertson et al., 1998).
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In other words, if y is a vector to be fit by isotonic regression, then the result would be a vector
z∗ = minz||y − z||2 subject to the constraint that zi ≤ zj for all i < j. One basic property of
isotonic regression is that if there is some i for which yj ≥ yi for all j greater than i and yj ≤ yi
for all j less than i, then the fit at i is z∗i = yi.
Isotonic regression is an appealing tool in the Phase I trials setting because the assumption
of toxicity increasing with dose is usually quite reasonable. After ending a Phase I trial, one
can apply isotonic regression to the vector pˆ = (t1/n1, t2/n2, . . . , tD/nD) using the weights
(n1, n2, . . . , nD) where ti is the number of DLTs seen at dose level i, ni is the number of patients
treated at dose level i, and D is the total number of dose levels considered. These values
and weights for isotonic regression have been used by other researchers to estimate the dose
toxicity curve (Stylianou and Flournoy, 2002), in which case, the isotonic regression estimator
is equivalent to the order restricted nonparametric maximum likelihood estimator (Sun, 1998).
After finding pˆ, there are several ways to estimate the MTD. Here, we consider the approach
used by Stylianou and Flournoy (2002), where the MTD estimate is the largest dose with an
estimated toxicity not exceeding a preset level. Recall that when a trial using the standard
design ends, the estimated MTD is the highest dose for which 6 people were treated and no
more than 1 person experienced a DLT. We shall call this particular dose level d. By the nature
of the standard design rules, ti/ni ≤ 1/6 for i ≤ d and ti/ni ≥ 1/3 for i > d. It now follows that
the isotonic regression estimate of the toxicity rate will be no more than 1/6 for i ≤ d and at
least 1/3 for i > d. Thus, if we set the target level pT to any value within the range [1/6, 1/3),
the dose level d will be the largest dose with an estimated toxicity not exceeding pT . Thus, for
1/6 ≤ pT < 1/3, this isotonic regression estimator of the MTD is equivalent to the MTD as
defined by the standard design.
4 Dose assignment for the Ji, Li, Bekele method and the
standard design
Ji, Li and Bekele note that when the priors used in their method are identical and independent
among dose levels, then the action to be taken with respect to treating future patients depends
on the cumulative number of patients and the cumulative number of DLTs in the current dose
group. As such, the behavior of the design can be described by a trial monitoring table. In Ji
et al. (2007), the trial monitoring table has columns corresponding to the number of patients
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treated at the current dose level and rows corresponding to the number of DLTs at the current
dose level. These elements completely specify future action in all cases where the next higher
dose level has not been found to have unacceptable toxicity.
With the standard design, future action also depends on the number of patients and the
number of DLTs seen in the current dose group. Likewise, the standard design rules in Table
1 can also be described by a trial monitoring table, as in Table 2. We found that when the Ji,
Li, Bekele method is used with cohorts of size 3, and parameters K1 = 1, K2 = 0.1, pT = 0.17,
ξ = 0.7, and prior B(0.005, 0.005) for example, a monitoring table identical to Table 2 was
yielded. A range of parameter values close to the ones above also produced the same monitoring
table. Thus, the actions during the trial are identical for both designs when the maximum sample
size in the Ji, Li, Bekele method is replaced by a stopping rule of 1 DLT out of 6 patients with the
next higher dose found to have unacceptable toxicity. That is, patients enrolled in either study
would be assigned treatment in exactly the same way. In addition, while the MTD estimates
of the two designs differ in general, they are identical for our choice of parameters. This is
because all the doses not excluded would have pˆi less than or equal to 1/6. Thus, all elements
of p∗ would be less than or equal to 1/6, which is less than pT = .17. Therefore, the highest
non-excluded dose would be selected, which would be the same dose selected by the standard
design.
We would like to suggest that a modification to the fixed stopping rule in the Ji, Li, Bekele
method would not alter its spirit. Moreover, we expect that a more data driven stopping rule
would be viewed as an enhancement by practitioners. As an example, if a dose was found to
have unacceptable toxicity early under their design, it may dictate treating a large number of
patients at the next lower dose level, regardless of how much information has been accumulated
at that level. A data driven stopping rule might mitigate such an issue.
5 The standard design and its potential to select an unsafe
MTD
There are many ways to assess how a clinical trial design would perform in terms of patient
safety. Here, we consider the standard design in terms of the underlying toxicity rate at the
estimated MTD. While research exists with respect to this aspect in the form of potentially
useful expressions (Reiner et al., 1999; Lin and Shih, 2001), our approach is to consider a worst
9
case dose toxicity scenario. In particular, we consider a dose toxicity curve that maximizes
the probability that the underlying toxicity rate at the estimated MTD is at or above a given
value. This consideration yields a simplified expression which can be used to, graphically or in
tabular form, examine the behavior of the standard design, or modifications to it. As a result,
additional insight about the performance of the standard design can be gleaned along with
possible comparisons to other designs which are minor modifications to the standard design.
These modifications could include changes in cohort size and/or the decision rule to expand or
escalate/de-escalate, for example. While some of these modifications are not used in practice,
we introduce them only to illustrate that it is relatively simple to experiment with different
design possibilities and examine their operating characteristics under this worst case.
Before proceeding, we introduce some notation. Let P (DLTMTD) be the underlying toxicity
rate at the estimated MTD. Let r(v) be the probability that the standard design would pick an
MTD for which P (DLTMTD) is greater than or equal to some value v. Note that here, v is not
meant to convey a target rate of DLTs, as such a quantity is not defined for the standard design.
Rather, v is any DLT rate of general interest. For example, if a clinical investigator felt that a
DLT rate of 30% represented an unacceptably high DLT rate for a future cancer therapeutic in
a particular cancer patient population, the investigator would be interested in the case where v
= 0.30.
We wish to find an upper bound for r(v). In order for r(v) to be nonzero, the dose toxicity
curve must have some dose level d for which pi ≥ v when i ≥ d and pi < v when i < d. To
maximize r(v), one must maximize the probability that at least one cohort is treated at dose
level d. One must also maximize the probability that the dose level does not de-escalate below
d given that at least one cohort is treated at dose level d. Thus, r(v) is maximized when pi = 0
for i < d and pi = v for i ≥ d. Note that r(v) is not a complementary cumulative distribution
function because the dose toxicity curve that maximizes r(v) is different for each value of v.
Using the rules of the standard design, Appendix A shows that
r(v) = 1− 3v(1− v)
2(1− (1− v)3) + (3v2(1− v) + v3)
1− (1− v)3(3v2(1− v) + v3)
We can also develop analogous expressions for modifications to the standard design. Consider
the following hybrid 1+2+3/3+3 design which is a variation of the two-stage design described
in Storer (2001). One patient is enrolled at the starting dose level, and if a DLT is not observed,
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then another patient is treated at the next highest dose level. This process continues until one
patient experiences a DLT, after which 2 more patients are treated at that dose, thereafter the
standard design is used for the rest of the trial. The cohort sizes would then be 2 or 3, so as to
make the dose group size divisible by 3 as in the standard 3 + 3 design. One can also consider
other modifications to the standard design where the number of DLTs that dictate the next
dose level to investigate are the same as that of the 3 + 3 but cohorts of size 2 or 4 are enrolled
instead of cohorts of size 3. Of course, such designs will on average select different MTDs with
different underlying DLT rates and will likewise have differing worst case scenarios.
In Figure 1, we compare the behavior of these worst case scenarios which are the maximum
probability of choosing an MTD with an underlying toxicity rate at or above v as a function of
v. Of the 4 designs described above, the 4+4 design appears to be the safest by this measure
and 2+2 the least safe. Interestingly, the curve for the 1+2+3/3+3 design falls between the
curve for the 2+2 design and the 3+3 design. It is also interesting to note that while the 2+2 is
virtually indistinguishable from the 1+2+3/3+3 through probabilities up to 0.2, they become
quite different at 0.6.
In addition to comparing the general behavior of different designs, these calculations may
help guide in the choice of design for a specific phase I trial. For example, consider a trial
involving a new cancer therapeutic that has shown promise in animal studies but which has the
potential to cause severe DLTs based upon the mechanism of action of the drug. In this scenario,
investigators would likely proceed cautiously with respect to how they treat the first patients
with this drug and the manner in which they escalate dosing. In this case, oncologists may be
particularly interested in an upper bound on the probability of selecting an unsafe MTD. If 0.25
is considered to be an unacceptably high rate of toxicity in this situation, we can see that the
3 + 3 design has, at most, a 57% chance of selecting an unacceptably high MTD whereas the
1+2+3/3+3 has, at most, a 74% chance. This observation, along with the designs’ behavior
in other scenarios, would presumably help inform the study design choice. Alternatively if we
consider a cancer therapeutic with future plans to treat patients with late stage cancer where
a more moderate rate of toxicity is acceptable, 0.35 may be considered to be the threshold for
what is considered unacceptably high. If we consider the alternative concern of selecting a dose
that is too low as the MTD, Figure 1 shows that the 4+4 design always has at least a 30% chance
of choosing an MTD with a DLT rate below 0.15, even though higher doses are acceptable in
these circumstances. This result may weigh against using such a design due to its relatively
11
high risk of choosing an MTD that is too low, which could negatively impact efficacy.
6 Discussion
We have shown that the standard design implicitly performs isotonic regression to estimate the
MTD. In addition, the rules of the standard design can be described using a trial monitoring
table of the form described by Ji et al. (2007).
Our results provide a more general way of viewing the standard design, which we hope will
encourage further development and examination of oncology phase Ia designs while accounting
for the realities of current oncologic practice. For example, one could change or add entries
to the trial monitoring table (Table 2) or change the stopping rule to allow for more cohorts
per dose level. One could also change the target rate for the isotonic regression or propose a
completely new method for assigning treatment or determining an MTD. Drug developers and
researchers are certainly ready and willing to consider new trial designs provided they truly
improve existing methods.
We have also illustrated the relationship between the 3 + 3 design and the Bayesian design
introduced by Ji, Li, and Bekele, the relationship being that the 3 + 3 can be seen as a special
case of the their Bayesian method with a modification to their stopping rule.
In addition, we were able to analytically identify the upper bound for the probability of
choosing an unsafe MTD with the 3 + 3 and similar designs. Similar analyses could straight-
forwardly be performed on other like designs like Storer’s best-of-five design (Storer, 2001) for
example. Examinations of these probability limits on more advanced designs, such as the Ji, Li,
Bekele method, may provide useful insights, although it is not immediately obvious how to do
so. The authors would like to also note that there are certainly more perspectives on how to
assess the operating characteristics of a phase I trial design, as has been done in the literature.
A common one being the expected number of patients treated at doses with high toxicity. One
could apply the framework presented here, considering the worst case scenario to find an upper
bound on the expected number of patients treated at doses for which the probability of toxicity
was at least v.
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A Worst case scenario calculations
Consider the 3+3 design. Let H be the index of the highest dose level visited during the trial,
and let K = H − d. Note that H is unbounded from above, so K is as well. Now,
r3+3(v) = 1−
∞∑
k=0
P (0 DLTs for 3 patients)kP (K = k|K ≥ k)
P (2 or more DLTs for 3 patients)k
= 1−
∞∑
k=0
((1− v)3)k [3v(1− v)2(1− (1− v)3) + (3v2(1− v) + v3)] (3v2(1− v) + v3)k
= 1− 3v(1− v)
2(1− (1− v)3) + (3v2(1− v) + v3)
1− (1− v)3(3v2(1− v) + v3)
Likewise, for the 2+2 design,
r2+2(v) = 1−
∞∑
k=0
P (0 DLTs for 2 patients)kP (K = k|K ≥ k)P (2 DLTs for 2 patients)k
= 1−
∞∑
k=0
((1− v)2)k [2v(1− v)(1− (1− v)2) + v2] (v2)k
= 1− 2v(1− v)(1− (1− v)
2) + v2
1− (1− v)2v2
and for the 4+4 design,
r4+4(v) = 1−
∞∑
k=0
P (0 DLTs for 4 patients)kP (K = k|K ≥ k)
P (2 or more DLTs for 4 patients)k
= 1−
∞∑
k=0
((1− v)4)k [4v(1− v)3(1− (1− v)4) + (1− (1− v)4 − 4v(1− v)3)]
(1− (1− v)4 − 4v(1− v)3)k
= 1− 4v(1− v)
3(1− (1− v)4) + (1− (1− v)4 − 4v(1− v)3)
1− (1− v)4(1− (1− v)4 − 4v(1− v)3)
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For the 1+2+3/3+3 design,
r1+2+3/3+3(v) = 1−
∞∑
k=0
P (0 DLTs for 1 patient)kP (K = k|K ≥ k)
P (2 or more DLTs for 5 patients)k
= 1−
∞∑
k=0
(1− v)k [v(1− (1− v)5)] (1− (1− v)5 − 5v(1− v)4)k
= 1− v(1− (1− v)
5)
1− (1− v)(1− (1− v)5 − 5v(1− v)4)
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Table 1: Rules for the standard design. The design stops enrolling patients after a dose is found
where at most 1 of 6 patients experiences a DLT and where at least 2 DLTs are observed at the
next highest dose.
DLTs Patients Action
0 3 Escalate
1 3 No change
≥ 2 3 De-escalate
≤ 1 6 Escalate
≥ 2 6 De-escalate
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Table 2: Alternate depiction of the standard design rules. The columns correspond to the number
of patients treated at the current dose level, and the rows correspond to the number of DLTs at
the current dose level. The elements specify the action, where ‘E’ means escalate, ‘S’ means stay
the same, and ‘DU’ means declare the current dose to be unacceptably toxic and de-escalate. The
design stops enrolling patients after a dose is found where at most 1 of 6 patients experiences a
DLT and where at least 2 DLTs are observed at the next highest dose.
3 6
0 E E
1 S E
2 DU DU
3 DU DU
4 DU
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Figure 1: max P(choose MTD at a dose where P (DLTMTD) ≥ v) vs. v. The designs are 3+3
(solid), 2+2 (dashed), 4+4 (dotted), and 1+2+3/3+3 (dotdashed).
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